<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Gentile, Francesco</dc:creator>
  <dc:creator>Deriu, Marco A.</dc:creator>
  <dc:creator>Barakat, Khaled</dc:creator>
  <dc:creator>Danani, Andrea</dc:creator>
  <dc:creator>Tuszynski, Jack</dc:creator>
  <dc:date>2018-02-16</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The Toll-Like Receptor 7 (TLR7) is an endosomal membrane receptor involved in the innate immune system response. Its best-known  small molecule activators are imidazoquinoline derivatives such as imiquimod (R-837) and resiquimod (R-848). Recently, an interaction  between R-837 and the colchicine binding site of tubulin was reported. To investigate the possibility of an interaction between structural  analogues of colchicine and the TLR7, a recent computational model for the dimeric form of the TLR7 receptor was used to determine a  possible interaction with a colchicine derivative called CR42-24, active as a tubulin polymerization inhibitor. The estimated values of the  binding energy of this molecule with respect to the TLR7 receptor were comparable to the energies of known binders as reported in a  previous study. The binding to the TLR7 was further assessed by introducing genetic transformations in the TLR7 gene in cancer cell lines  and exposing them to the compound. A negative shift of the IC50 value in terms of cell growth was observed in cell lines carrying the  mutated TLR7 gene. The reported study suggests a possible interaction between TLR7 and a colchicine derivative, which can be explored  for rational design of new drugs acting on this receptor by using a colchicine scaffold for additional modifications.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://n2t.net/ark:/12658/srd1319108</dc:identifier>
  <dc:identifier>https://susi.usi.ch/global/documents/319108</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319108/files/Gentile_P_2018.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/ph11010022</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319108</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Pharmaceuticals. - 2018, vol. 11, no. 1, p. 22</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">TLR7</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Colchicine</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Imiquimod</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Innate immune system</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Off-target interaction</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns6="xml" ns6:lang="en">A novel interaction between the TLR7 and a colchicine derivative revealed through a computational and experimental study</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
